# 18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant

> **NCT02379377** · PHASE1 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 110 (estimated)

## Conditions studied

- Adult Hepatocellular Carcinoma
- Resectable Hepatocellular Carcinoma
- Cholangiocarcinoma
- Benign Liver Tumor
- Metastases to Liver

## Interventions

- **BIOLOGICAL:** Fluorine F 18 L-glutamate Derivative 18F-FSPG
- **BIOLOGICAL:** Carbon C 11 Acetate
- **PROCEDURE:** Positron Emission Tomography
- **OTHER:** Laboratory Biomarker Analysis
- **BIOLOGICAL:** Fluorine F 18 2-deoxy-2-(18F)fluoro-D-glucose

## Key facts

- **NCT ID:** NCT02379377
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-02-15
- **Primary completion:** 2027-05-31
- **Final completion:** 2027-05-31
- **Target enrollment:** 110 (ESTIMATED)
- **Last updated:** 2026-03-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02379377

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02379377, "18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02379377. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*